More Information About CAR T-cell Therapy
For Patients and Caregivers
From the University of Chicago Medicine:
The University of Chicago Medicine is one of the first sites in the U.S. certified to offer CAR T-cell therapy for pediatric acute lymphoblastic leukemia (ALL).
Immunotherapies – powerful treatments that activate the body’s own defense mechanisms to attack cancer cells and halt tumor growth – are revolutionizing the way we treat cancer. From basic research to patient care, the University of Chicago Medicine is at the forefront of these new and promising treatments.
Other trusted resources:
Scientific Journal Articles
Read scientific journal articles about CAR T-cell therapy research.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Grupp SA, Kalos M, Barrett D, et al. New England Journal of Medicine, 368(16), April 18, 2013.
Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels.
Kochenderfer JN, Somerville RPT, Lu T, et al. Journal of Clinical Oncology, 35(16), June 1, 2017.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Maude SL, Frey N, Shaw PA, et al. New England Journal of Medicine, 371(16), October 16, 2014.
UChicago Medicine Cancer Care Locations
Request an Appointment
Please complete this secure form to request an appointment with a UChicago Medicine CAR T-cell therapy expert. A representative will contact you within one to two business days to help you schedule the appointment.
Please note this electronic request form is not for same- or next-day appointments. If you prefer to speak with someone directly, please call 1-844-482-7823. If you have symptoms of an urgent nature, please call your doctor or go to the emergency room immediately.